Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Avigan

Showing results (21-30 of 114) with videos related to

Pageof 12
Sort By:
Molecular Therapy. Methods & Clinical Development|May 9, 2017
Dendritic Cell Therapies for Hematologic MalignanciesMatthew Weinstock, Jacalyn Rosenblatt, David Avigan
Best Practice & Research. Clinical Haematology|November 30, 2025
CAR-T cell therapy for multiple myeloma: An update on the current state and future potentialPrateek Pophali, Jacalyn Rosenblatt, David Avigan
Current Hematologic Malignancy Reports|September 5, 2015
Immunotherapy for Multiple Myeloma, Past, Present, and Future: Monoclonal Antibodies, Vaccines, and Cellular TherapiesRebecca Karp Leaf, Hearn Jay Cho, David Avigan
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 12, 2021
Vaccination as Immunotherapy in Hematologic MalignanciesJessica Liegel, Matthew Weinstock, Jacalyn Rosenblatt, et al.
Blood|March 18, 2014
Targeting MUC1-C is synergistic with bortezomib in downregulating TIGAR and inducing ROS-mediated myeloma cell deathLi Yin, Turner Kufe, David Avigan, et al.
Cancer Chemotherapy and Pharmacology|July 11, 2006
A novel isocoumarin derivative induces mitotic phase arrest and apoptosis of human multiple myeloma cellsTakeshi Kawano, Naoki Agata, Surender Kharbanda, et al.
Blood Reviews|February 25, 2018
Anti-cancer vaccine therapy for hematologic malignancies: An evolving eraMyrna R Nahas, Jacalyn Rosenblatt, Hillard M Lazarus, et al.
Best Practice & Research. Clinical Haematology|September 7, 2025
Cancer vaccines in hematologic malignancy: A systematic review of the rational and evidence for clinical useT Anders Olsen, Kevin J Barnum, David Avigan, et al.
Rambam Maimonides Medical Journal|November 12, 2014
Dendritic cell cancer vaccines: from the bench to the bedsideTamar Katz, Irit Avivi, Noam Benyamini, et al.
Blood Advances|June 15, 2018
Possible reactivation of chromosomally integrated human herpesvirus 6 after treatment with histone deacetylase inhibitorIoannis Politikos, Malgorzata McMasters, Christine Bryke, et al.
Pageof 12

Showing results (21-30 of 114) with videos related to

Sort By:
Pageof 12
Molecular Therapy. Methods & Clinical Development|May 9, 2017
Dendritic Cell Therapies for Hematologic MalignanciesMatthew Weinstock, Jacalyn Rosenblatt, David Avigan
Best Practice & Research. Clinical Haematology|November 30, 2025
CAR-T cell therapy for multiple myeloma: An update on the current state and future potentialPrateek Pophali, Jacalyn Rosenblatt, David Avigan
Current Hematologic Malignancy Reports|September 5, 2015
Immunotherapy for Multiple Myeloma, Past, Present, and Future: Monoclonal Antibodies, Vaccines, and Cellular TherapiesRebecca Karp Leaf, Hearn Jay Cho, David Avigan
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 12, 2021
Vaccination as Immunotherapy in Hematologic MalignanciesJessica Liegel, Matthew Weinstock, Jacalyn Rosenblatt, et al.
Blood|March 18, 2014
Targeting MUC1-C is synergistic with bortezomib in downregulating TIGAR and inducing ROS-mediated myeloma cell deathLi Yin, Turner Kufe, David Avigan, et al.
Cancer Chemotherapy and Pharmacology|July 11, 2006
A novel isocoumarin derivative induces mitotic phase arrest and apoptosis of human multiple myeloma cellsTakeshi Kawano, Naoki Agata, Surender Kharbanda, et al.
Blood Reviews|February 25, 2018
Anti-cancer vaccine therapy for hematologic malignancies: An evolving eraMyrna R Nahas, Jacalyn Rosenblatt, Hillard M Lazarus, et al.
Best Practice & Research. Clinical Haematology|September 7, 2025
Cancer vaccines in hematologic malignancy: A systematic review of the rational and evidence for clinical useT Anders Olsen, Kevin J Barnum, David Avigan, et al.
Rambam Maimonides Medical Journal|November 12, 2014
Dendritic cell cancer vaccines: from the bench to the bedsideTamar Katz, Irit Avivi, Noam Benyamini, et al.
Blood Advances|June 15, 2018
Possible reactivation of chromosomally integrated human herpesvirus 6 after treatment with histone deacetylase inhibitorIoannis Politikos, Malgorzata McMasters, Christine Bryke, et al.
Pageof 12